Edition:
United States

Health News

Photo

AstraZeneca's immunotherapy drug wins key lung cancer approval 3:14am EST

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

More Headlines

Preemies and underweight babies more likely to have low IQs

(Reuters Health) - Babies who are born much too soon or who arrive weighing too little may not score as high on intelligence tests during childhood as full-term infants, a research review suggests.

12:28pm EST

New acne diagnoses linked to increased depression risk

(Reuters Health) - In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population, a new study shows.

10:15am EST
Photo

Novartis readies to auction U.S. generic pills business: sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

Feb 16 2018

U.S. faces shortage of developmental and behavioral pediatrics specialists

(Reuters Health) - A shortage of clinicians specializing in pediatric behavioral and developmental disorders is translating into long wait times for new patient appointments amid surging demand, a new study suggests.

Feb 16 2018

Health Watch Graphics